Cargando…

Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment

Breast cancer represents the most common malignancy among women in the world. Although immuno-, chemo- and radiation therapy are widely recognized as the therapeutic trifecta, new strategies in the fight against breast cancer are continually explored. The local microenvironment around the tumor play...

Descripción completa

Detalles Bibliográficos
Autores principales: Brett, Elizabeth, Duscher, Dominik, Pagani, Andrea, Daigeler, Adrien, Kolbenschlag, Jonas, Hahn, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694078/
https://www.ncbi.nlm.nih.gov/pubmed/36430633
http://dx.doi.org/10.3390/ijms232214159
_version_ 1784837708769656832
author Brett, Elizabeth
Duscher, Dominik
Pagani, Andrea
Daigeler, Adrien
Kolbenschlag, Jonas
Hahn, Markus
author_facet Brett, Elizabeth
Duscher, Dominik
Pagani, Andrea
Daigeler, Adrien
Kolbenschlag, Jonas
Hahn, Markus
author_sort Brett, Elizabeth
collection PubMed
description Breast cancer represents the most common malignancy among women in the world. Although immuno-, chemo- and radiation therapy are widely recognized as the therapeutic trifecta, new strategies in the fight against breast cancer are continually explored. The local microenvironment around the tumor plays a great role in cancer progression and invasion, representing a promising therapeutic target. CCL5 is a potent chemokine with a physiological role of immune cell attraction and has gained particular attention in R&D for breast cancer treatment. Its receptor, CCR5, is a well-known co-factor for HIV entry through the cell membrane. Interestingly, biology research is unusually unified in describing CCL5 as a pro-oncogenic factor, especially in breast cancer. In silico, in vitro and in vivo studies blocking the CCL5/CCR5 axis show cancer cells become less invasive and less malignant, and the extracellular matrices produced are less oncogenic. At present, CCR5 blocking is a mainstay of HIV treatment, but despite its promising role in cancer treatment, CCR5 blocking in breast cancer remains unperformed. This review presents the role of the CCL5/CCR5 axis and its effector mechanisms, and names the most prominent hurdles for the clinical adoption of anti-CCR5 drugs in cancer.
format Online
Article
Text
id pubmed-9694078
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96940782022-11-26 Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment Brett, Elizabeth Duscher, Dominik Pagani, Andrea Daigeler, Adrien Kolbenschlag, Jonas Hahn, Markus Int J Mol Sci Review Breast cancer represents the most common malignancy among women in the world. Although immuno-, chemo- and radiation therapy are widely recognized as the therapeutic trifecta, new strategies in the fight against breast cancer are continually explored. The local microenvironment around the tumor plays a great role in cancer progression and invasion, representing a promising therapeutic target. CCL5 is a potent chemokine with a physiological role of immune cell attraction and has gained particular attention in R&D for breast cancer treatment. Its receptor, CCR5, is a well-known co-factor for HIV entry through the cell membrane. Interestingly, biology research is unusually unified in describing CCL5 as a pro-oncogenic factor, especially in breast cancer. In silico, in vitro and in vivo studies blocking the CCL5/CCR5 axis show cancer cells become less invasive and less malignant, and the extracellular matrices produced are less oncogenic. At present, CCR5 blocking is a mainstay of HIV treatment, but despite its promising role in cancer treatment, CCR5 blocking in breast cancer remains unperformed. This review presents the role of the CCL5/CCR5 axis and its effector mechanisms, and names the most prominent hurdles for the clinical adoption of anti-CCR5 drugs in cancer. MDPI 2022-11-16 /pmc/articles/PMC9694078/ /pubmed/36430633 http://dx.doi.org/10.3390/ijms232214159 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Brett, Elizabeth
Duscher, Dominik
Pagani, Andrea
Daigeler, Adrien
Kolbenschlag, Jonas
Hahn, Markus
Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
title Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
title_full Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
title_fullStr Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
title_full_unstemmed Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
title_short Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
title_sort naming the barriers between anti-ccr5 therapy, breast cancer and its microenvironment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694078/
https://www.ncbi.nlm.nih.gov/pubmed/36430633
http://dx.doi.org/10.3390/ijms232214159
work_keys_str_mv AT brettelizabeth namingthebarriersbetweenanticcr5therapybreastcanceranditsmicroenvironment
AT duscherdominik namingthebarriersbetweenanticcr5therapybreastcanceranditsmicroenvironment
AT paganiandrea namingthebarriersbetweenanticcr5therapybreastcanceranditsmicroenvironment
AT daigeleradrien namingthebarriersbetweenanticcr5therapybreastcanceranditsmicroenvironment
AT kolbenschlagjonas namingthebarriersbetweenanticcr5therapybreastcanceranditsmicroenvironment
AT hahnmarkus namingthebarriersbetweenanticcr5therapybreastcanceranditsmicroenvironment